Table 1.
General Features of KTR, Kidney Donors, and Participants From the General Population (GPhealthy and PGCKD+3).
| Variable | KTR (n = 141), n (%) | LKD (n = 112), n (%) | PGCKD+3 (n = 37), n (%) | GPhealthy (n = 76), n (%) |
|---|---|---|---|---|
| Age (years) | 37 ± 13 (18-75) | 45 ± 13 (18-75) | 48.5 ± 18.4 (18-73) | 57.5 ± 14.1 (19-75) |
| Male | 74 (53) | 58 (52) | 16 (43) | 37 (49) |
| BMI (kg/m2): | 24.8 ± 3.2 | 25 ± 2.8 | 24.9 ± 2.1 | 24.5 ± 2.6 |
| <18.49 | 6 (4) | — | 1 (3) | 2 (3) |
| 18.5-24.99 | 74 (53) | 51 (46) | 10 (28) | 35 (45) |
| 25-29.99 | 61 (43) | 61 (54) | 18 (49) | 47 (62) |
| Complication post-surgical: | ||||
| Diabetes type 2 | 24 (17) | 6 (5) | 2 (2.6) | 5 (6.6) |
| Hypertension | 69 (49) | 24 (21) | — | — |
| Evolution time (months) | 51 ± 65 | 38 ± 33 | ||
| After | (12-396) | (12-240) | N/A | N/A |
| Previous disease: | ||||
| Unknown | 67 (48) | |||
| Diabetes mellitus | 17 (12) | |||
| Renal hypoplasia | 9 (6) | N/A | N/A | N/A |
| Systemic lupus erythematosus in remission | 15 (11) | |||
| Others | 33 (22) | |||
| Induction: | ||||
| Thymoglobulin | 22 (16) | N/A | N/A | N/A |
| Basiliximab | 104 (74) | |||
| No induction | 15 (10) | |||
| Kind of donor: | ||||
| Live related donor | 112 (79) | |||
| Live non-related donor | 18 (13) | N/A | N/A | N/A |
| Dead donor | 11 (8) | |||
| Maintenance therapy: | ||||
| Tacrolimus | 123 (87) | |||
| Cyclosporine | 11 (8) | N/A | N/A | N/A |
| Sirolimus | 3 (2) | |||
| No maintenance therapy | 4 (3) | |||
| Replacement therapy: | ||||
| Hemodialysis | 62 (44) | |||
| Peritoneal dialysis | 56 (40) | N/A | N/A | N/A |
| Combined therapy | 3 (2) | |||
| No therapy | 20 (14) | |||
Note. Sociodemographic and clinical features of the 3 populations. Every feature is presented with its mean ± standard deviation and frequencies. KTR = kidney transplant recipient; GPhealthy and PGCKD+3, PG: participants from the general population; LKD = live kidney donor; BMI = body mass index; CKD = chronic kidney disease.